Page 3 - Layout 1
P. 3
leukomalacia, retinopathy of prematurity, seizures, e. multiple gestation?
sepsis, and stillbirth for the following subgroups:
f. racial or ethnic subgroups?
a. women <28 weeks of gestation (extremely
g. women with previous preterm birth?
preterm)?
h. women with history of preeclampsia?
b. women between 28 weeks and 31 weeks of
gestation (very preterm)? i. women with RPTL and women without RPTL?
c. women between 32 weeks and 33 weeks of Key Question 3: increase the maternal harms of
gestation (preterm)? arrhythmia, heart failure, hyperglycemia,
hypokalemia, maternal mortality, myocardial
d. women between 34 weeks and 36 weeks of
infarction, pulmonary edema, or refractory
gestation (later preterm)?
hypotension, or result in an increased rate of
e. multiple gestation? maternal discontinuation of therapy or maternal
withdrawal due to adverse effects (Withdrawal-AE)?
f. racial or ethnic subgroups?
Key Question 4: increase the neonatal terbutaline-
g. women with previous preterm birth?
related harms of hypoglycemia, hypocalcemia, and
h. women with history of preeclampsia? ileus?
i. women with RPTL and women without RPTL? Key Question 5: Can the differences in the outcomes
Key Question 2: improve other surrogate outcomes, above be partially explained by the differences in
including gestational age at delivery, incidence of level of care (e.g., frequency of followup, nurse visits,
delivery at various gestational ages (<28 weeks, < 32 concomitant treatment, etc.) and level of activity
weeks, <34 weeks, <37 weeks), mean prolongation of (e.g., other children in the home, marital/support
pregnancy (days), birth weight, ratio of birth status, working status, bedrest, etc.) between the
weight/gestational age at delivery, pregnancy terbutaline pump group and the comparator group?
prolongation index, need for assisted ventilation,
Key Question 6: What is the incidence of failure of
need for oxygen per nasal cannula, and neonatal
the pump device used for terbutaline infusion,
intensive care unit (NICU) admission for the
including missed doses, dislodgment, and overdose?
following subgroups:
a. women <28 weeks of gestation (extremely Analytic Framework
preterm)?
We developed an analytic framework depicting links
b. women between 28 weeks and 31 weeks of between the intervention and related clinical and
gestation (very preterm)? intermediate efficacy and harms outcomes and other
c. women between 32 weeks and 33 weeks of unintended adverse effects (Figure A). In the framework
gestation (preterm)? below, the key questions of interest can be seen to
encompass a holistic inquiry of the topic.
d. women between 34 weeks and 36 weeks of
gestation (later preterm)?
3